BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21642392)

  • 1. Interaction of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates with human liver microsomal cytochromes P450: comparison with free doxorubicin.
    Masek V; Anzenbacherová E; Etrych T; Strohalm J; Ulbrich K; Anzenbacher P
    Drug Metab Dispos; 2011 Sep; 39(9):1704-10. PubMed ID: 21642392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
    Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
    Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond.
    Ríhová B; Etrych T; Sírová M; Kovár L; Hovorka O; Kovár M; Benda A; Ulbrich K
    Mol Pharm; 2010 Aug; 7(4):1027-40. PubMed ID: 20524698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
    Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
    J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450.
    Masek V; Anzenbacherová E; Machová M; Brabec V; Anzenbacher P
    Anticancer Drugs; 2009 Jun; 20(5):305-11. PubMed ID: 19378397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro.
    Subr V; Sivák L; Koziolová E; Braunová A; Pechar M; Strohalm J; Kabešová M; Ríhová B; Ulbrich K; Kovář M
    Biomacromolecules; 2014 Aug; 15(8):3030-43. PubMed ID: 24978588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.
    Zhou Z; Li L; Yang Y; Xu X; Huang Y
    Biomaterials; 2014 Aug; 35(24):6622-35. PubMed ID: 24814427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel star HPMA-based polymer conjugates for passive targeting to solid tumors.
    Etrych T; Strohalm J; Chytil P; Říhová B; Ulbrich K
    J Drug Target; 2011 Dec; 19(10):874-89. PubMed ID: 21978286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
    Li L; Zhou M; Huang Y
    Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
    Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of acetylcholinesterase oxime-type reactivators K-48 and HI-6 on human liver microsomal cytochromes P450 in vitro.
    Veinlichova A; Jancova P; Siller M; Anzenbacher P; Kuca K; Jun D; Fusek J; Anzenbacherova E
    Chem Biol Interact; 2009 Aug; 180(3):449-53. PubMed ID: 19539805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates.
    Paul A; Vicent MJ; Duncan R
    Biomacromolecules; 2007 May; 8(5):1573-9. PubMed ID: 17419585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
    Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
    Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
    Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
    Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines.
    Greco F; Vicent MJ; Penning NA; Nicholson RI; Duncan R
    J Drug Target; 2005; 13(8-9):459-70. PubMed ID: 16332571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
    Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
    J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
    Peng ZH; Kopeček J
    J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of isoflavonoids with human liver microsomal cytochromes P450: inhibition of CYP enzyme activities.
    Kopečná-Zapletalová M; Krasulová K; Anzenbacher P; Hodek P; Anzenbacherová E
    Xenobiotica; 2017 Apr; 47(4):324-331. PubMed ID: 27312150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity.
    Mrkvan T; Sirova M; Etrych T; Chytil P; Strohalm J; Plocova D; Ulbrich K; Rihova B
    J Control Release; 2005 Dec; 110(1):119-29. PubMed ID: 16269198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.